After a generation spent shaping the growth and development of biopharma clusters, Alexandria Real Estate Equities executive chairman and founder Joel Marcus recently spoke publicly about what will most likely drive the upcoming generation of hubs for biopharma and other emerging life sciences. “If we focus for a moment on the next life science frontier, it’s pretty clear that the sheer scale of unmet medical needs for patients suffering from diseases of the brain is quite staggering, the cost to society enormous,” Marcus told analysts on Alexandria’s quarterly conference call July 30, according to a transcript published by Seeking Alpha. He cited the growing cost of treating dementia and Alzheimer’s disease, and the nation’s opioid epidemic. “Discovering new treatments and cures for diseases of the brain has become a goal of ever-increasing urgency and one on which Alexandria is super-laser focused on with our financial capital as well as our human capital,” Marcus said. Marcus also emphasized Click Here For Complete Article Text
|
|||||||||||||||||||||||||||
| Application Sequencing | |||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
| Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | ||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||||||